Signature of TL1A (TNFSF15) signaling pathway
AssigneeCedars-Sinai Medical Center
InventorsKathrin S. Michelsen, Stephan R. Targan
Life of this patent
Estimating the term…
Abstract
The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL17 secretion from TL17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.
Claims10
A method of monitoring an effectiveness of an anti-TL1A therapy to reduce expression of TL1A in a subject, the method comprising:
- a) measuring in a sample obtained from a subject with an inflammatory bowel disease or allergic lung inflammation a level of expression of interleukin-9 (IL-9);
- b) detecting an elevated level of expression of IL-9 in the sample as compared to a level of expression of IL-9 in an individual who does not have the inflammatory bowel disease or allergic lung inflammation;
- c) administering to the subject an anti-TL1A antibody;
- d) determining a presence of a downregulation of IL-9;
- and
- e) determining that the administration of the anti-TL1A antibody is effective to reduce an elevated level of TL1A in the subject.
A method of treating an inflammatory bowel disease or allergic lung inflammation in a subject with an anti-TL1A-antibody, the method comprising:
- a) administering to the subject a dosage of the anti-TL1A antibody;
- b) determining whether the dosage of the anti-TL1A antibody is therapeutically effective to treat the inflammatory bowel disease or allergic lung inflammation in the subject by determining a presence of a downregulation of interleukin-9 (IL-9);
- and
- c) continue administering the anti-TL1A antibody to the subject administering, to the subject, a second dosage of the TL1A antibody.
Dependencies are inferred from the claim text.